New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
Author:
Funder
Program of Shanghai Academic Research Leader
Publisher
Elsevier BV
Subject
Cancer Research,Genetics,Oncology
Reference142 articles.
1. Hepatocellular carcinoma;Llovet;Nat. Rev. Dis. Primers,2016
2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N. Engl. J. Med.,2008
3. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice;Lo;Hepatology,2015
4. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling;Wilhelm;Mol. Cancer Ther.,2008
5. Sorafenib
Cited by 74 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Disulfidptosis-related gene expression reflects the prognosis of drug-resistant cancer patients and inhibition of MYH9 reverses sorafenib resistance;Translational Oncology;2024-11
2. Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429‐dependent m6A modification of CCR9;Journal of Medical Virology;2024-08-29
3. Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression;International Journal of Molecular Sciences;2024-08-17
4. Hepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies;Cancer Letters;2024-08
5. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3